A B S T R A C T Human lymphocytes are known to possess a catecholamine-responsive adenylate cyclase which has typical P-adrenergic specificity. To identify directly and to quantitate these P-adrenergic receptors in human lymphocytes, (-) [2H]alprenolol, a potent P-adrenergic antagonist, was used to label binding sites in homogenates of human mononuclear leukocytes. Binding of (-) These results demonstrate the feasibility of using direct binding methods to study fi-adrenergic receptors in a human tissue. They also provide an experimental approach to the study of states of altered sensitivity to catecholamines at the receptor level in man.
INTRODUCTION
Specific membrane receptor sites for a number of hormones have been identified in a variety of tissues by direct binding studies using biologically active radiolabeled compounds. The application of these techniques to the investigation of possible molecular alterations of hormone receptors in human disease has been limited by the relative inaccessability of large quantities of human tissue for binding studies. Recently, Soll et al. (1) demonstrated by direct binding studies that insulin receptor defects in thymic lymphocytes mirrored defects in insulin receptors in adipose and hepatic tissue from insulin-resistant animals. Subsequently, Archer et al. (2) used insulin binding studies in human peripheral leukocytes to detect insulin receptor defects in human insulinresistant states.
Alterations in the 8-adrenergic receptor have been proposed in human pathological states characterized by
The Journal of Clinical Investigation Volume 57 January 1976 -149-155 altered sensitivity to catecholamines. These include hyperthyroidism (3) and asthma (4) . The identification of 8-adrenergic receptors in a human tissue by direct binding studies would make possible the investigation of the role of P-adrenergic receptor alterations in these diseases. The presence of P-adrenergic receptors in circulating leukocytes has been indicated by the demonstration in these cells of adenylate cyclase activity that responds to catecholamines with a typical P-adrenergic specificity (5) . However, these receptors have not previously been studied by direct binding methods.
Early attempts at identifying f-adrenergic receptors by direct binding methods with [3H] catecholamines were associated with discrepancies between binding data and data from physiological response measurements. Thus, more refined and stringent criteria have been proposed (6, 7) for f-adrenergic receptor identification:
(a) 8 (-) [3H]Alprenolol' used for these studies has a specific activity of 17 Ci/mmol and has biological activity and chromatographic properties identical to native (-) alprenolol (9) . Other compounds used in this study were: (-)isoproterenol bitartrate, (-)epinephrine bitartrate, (-)norepinephrine bitartrate, (+ ) normetanephrine, dihydroxymandelic acid, and dopamine (Sigma Chemical Co., St. Louis, Mo.) ; (+) isoproterenol bitartrate, (+) epinephrine bitar-
Alprenolol" refers to the compound which was prepared by New England Nuclear by catalytic reduction of (-) alprenolol (Hassle) with tritium gas using paladium as the catalyst. Mass spectroscopy of (-) [3H]alprenolol has recently demonstrated that its structure is that of dihydroalprenolol. Hence tritiation of alprenolol probably occurs at the unsaturated bond in the aliphatic chain on position 2 of the aromatic ring. 
Leukocyte preparations
The various cell preparations were isolated from heparinized peripheral blood (100-200 cc) of healthy human volunteers as described below:
Mononuclear leukocytes (MNL's).2 Blood was centrifuged on Ficoll-Hypaque density gradients using the method of Boyum (11) . The MNL fraction contained approximately 85%o small lymphocytes, 13%o monocytes, and less than 2%o polymorphonuclear leukocytes by morphological criteria using Turk's solution. These cells were removed from the gradients and washed in 0.02 M phosphate-buffered saline, pH 7.2 containing 0.1%o gelatin and 5 mM MgCln and 0.15 mM CaCls (PBS) . After centrifugation at 400 g for 15 min at 4VC, the mononuclear cell pellets were resuspended in 20 ml 50 mM Tris-HC1 (pH 8.1 at 40C) containing 10 mM MgC12 (incubation buffer) and homogenized in a Potter-Elvejhem glass homogenizer fitted with a motordriven Teflon pestle. The homogenate was centrifuged at 25,000 g for 15 min, the pellet was washed twice with cold incubation buffer, and the final pellet was then resuspended in 3 ml of incubation buffer resulting in a suspension containing about 3 mg protein/ml. This mononuclear cell homogenate was used in all experiments unless otherwise specified.
Purified lymphocytes. Portions of the MNL fractions isolated from the Ficoll-Hypaque gradients were washed in PBS, standardized to contain 1 X 10' cells/ml and passed twice over a nylon mesh column at 37°C at a rate of 1 ml/min. This procedure, designed to remove monocytes and polymorphonuclear leukocytes which adhere to the nylon mesh, resulted in a purified lymphocyte preparation containing at least 99%9 small lymphocytes by morphological criteria. After one wash in PBS the cells were homogenized in incubation buffer, centrifuged, washed, and resuspended as described for the MNL preparation above.
Polyniorphonuclear leukocyte (PMN) preparation. PMN preparations were obtained from the erythrocyte-PMN pellets produced after fractioning blood on Ficoll-Hypaque gradients. These pellets were diluted 1: 2 with PBS and then mixed with an equal volume of 3% (wt/vol) high molecular weight dextran (T250, Pharmacia Fine Chemicals Inc., Piscataway, N. J.) in PBS. The erythrocytes were allowed to *sediment for 25 min at 250C and the supernate was removed. These supernates, containing at least 98% PMNs, were washed in PBS and then homogenized in incubation buffer, centrifuged, washed, and resuspended as described above for the MNL preparation.
Erythrocvte preparation. The erythrocyte sediments obtained after dextran sedimentation of the erythrocyte-PMN pellets derived from Ficoll-Hypaque gradients were washed three times in PBS. Erythrocytes were then homogenized in incubation buffer, centrifuged, washed, and resuspended as described above for the MNL preparation. by rapidly diluting a 125-sl incubation aliquot with 2 ml of ice-cold incubation buffer followed by rapid vacuum filtration of the diluted incubate through Whatman GFC glass fiber filters. The filters were rapidly washed by vacuum filtration of 10 ml of ice-cold incubation buffer. After drying, filters were placed directly into triton/toluenebased scintillation cocktail and counted in a Packard liquid scintillation spectrometer (Packard Instrument Co., Downers Grove, Ill.) at an efficiency of 40%.
In each experiment "nonspecific" binding to homogenate protein was determined by measuring the amount of radioactivity retained on filters when incubations were performed in the presence of a high concentration (10 AM) of (±)-propranolol. "Specific binding," defined as total binding to homogenate protein minus nonspecific binding, was 80-90%o of the total (-) [3H alprenolol bound to homogenate protein. A very small amount of (-) [8H]alprenolol (about 0.2%o of the total tracer filtered) was also adsorbed to the glass fiber filters. This small "filter blank" was not affected by the presence of unlabeled f8-adrenergic agonists and antagonists. The binding values reported in all figures and tables refer to specific binding as defined above.
Adenylate cyclase assay
Adenylate cyclase activity of mononuclear cell homogenates was assayed as previously described (12) . Mononuclear cell homogenates rather than intact cells were used in these adenylate cyclase assays so that the results would be directly comparable to the binding studies which were also done on mononuclear cell homogenates. Incubations were performed in a volume of 50 Asl which contained 30 mM Tris HCO (pH 7.4), 5 mM MgC12, 0.1 mM cAMP, 1.5 mM ATP, [a-"P]ATP (1-2 X 106 cpm), 5 mM phosphoenolpyruvate, pyruvate kinase (40 ,ug/ml), and myokinase (20 ,ug/ml). Incubations were for 15 min at 37°C and were stopped by addition of 1 ml of a solution containing
[3H]cAMP (15,000 cpm/ml), 100 ,g ATP, and 50 Atg cAMP. [3'P] cAMP that was formed was isolated by the method of Salomon et al. ( 13) .
Protein was determined by the method of Lowry et al. (14) . Fig. 2A) with an order of potency identical to the order of potency of these agonists in activating adenylate cyclase in human leukocytes (Fig. 2B ): (-) isoproterenol> (-) epinephrine > (-) norepinephrine. Moreover, the absolute values of the dissociation constants computed from binding experiments were virtually identical with those derived from adenylate cyclase activation (Table I ). The concentrations of the (+)stereoisomers of fi-adrenergic agonists required to cause half-maximal inhibition of binding were 9-300-fold higher than those of the corresponding (-)stereoisomers, indicating marked stereospecificity of binding for the agonists. Similarly the adenylate cyclase response (Fig. 2B) to these agents was highly stereospecific.
(-) Propranolol, a 8-adrenergic antagonist of isoproterenol-stimulated adenylate cyclase (Fig. 3) , potently inhibited binding (Fig. 4) 3 ). Inhibition of (-) [3H]alprenolol binding was highly stereospecific, the (-) stereoisomer of propranolol being 160 times more potent than the (+)stereoisomer.
(-) Alprenolol potently antagonized isoproterenolstimulated adenylate cyclase (Fig. 3) with a calculated KD of 9 nM. This value is in good agreement with the KD for (-) [3H] alprenolol (10 nM) estimated from the concentration of (-) [3H]alprenolol which occupies 50% of the receptors (Fig. 1) .
Compounds devoid of P-adrenergic physiological effects were not effective inhibitors of (-) [3H]alprenolol binding. The catecholamine metabolites dihydroxymandelic acid and normetanephrine caused only 27 and 36% inhibition of binding at the high concentration of 1 mM. Likewise the catecholamine precursor, dopamine, and pyrocatechol at 1 mM inhibited only 35 and 15% of the binding, respectively. The potent a-adrenergic antagonist, phentolamine, caused only 30% inhibition of the binding at 0.1 mM, a concentration over four orders of magnitude higher than its physiological dissociation constant for the a-adrenergic receptor (15 (Table I) . Since the PMN contamination of the mononuclear cell preparations is less than 2%, however, the binding due to contaminating PMNs in the preparation is insignificant. The absence of binding to human erythrocytes is in agreement with the previous failure to demonstrate catecholamine-sensitive adenylate cyclase activity in human erythrocytes (16) . DISCUSSION The (-) [5H]alprenolol binding sites studied in these mononuclear cell homogenates display the kinetics, saturability, stereospecificity, and affinity for adrenergic agonists and antagonists expected of true 8- and (-) propranolol. Adenylate cyclase assays were performed as described in Methods. For curves done in the presence of antagonist, the antagonist was added to homogenates just before exposure to (-)isoproterenol in the adenylate cyclase assay. Each value shown is the mean±SD of three to six determinations. Basal adenylate cyclase activity was 50 pmol/mg protein per min. Maximal stimulation was 50% above basal activity. The KD was calculated using the equation (Reference 15): KD = [antagonist]/(CR-l) where CR (concentration ratio) is the ratio of equiactive concentrations of isoproterenol in the presence and absence of a given fixed concentration of the antagonist. sites in amphibian erythrocytes (8, 9) and canine myocardium (10) . The kinetics of (-) [5H]alprenolol binding are consistent with the rapid forward and reverse rates found previously for catecholamine activation of adenylate cyclase-coupled 9-adrenergic receptors (9) . The number of (-) [3H]alprenolol binding sites per lymphocyte (2, (Fig. 2) . Thus the specificity, affinity, and stereospecificity characteristic of P-adrenergic physiological responses were apparent in both the binding of (-) [5H]alprenolol and in the adenylate cyclase response in mononuclear cell homogenates.
A previous study of catecholamine-stimulated cyclic AMP accumulation in intact leukocytes by Bourne and Melmon (5) reported an order of potency (isoproterenol = epinephrine > norepinephrine) which is discrepant with the potency order (isoproterenol > epinephrine > norepinephrine) reported in the present study for catecholaftine activation of adenylate cyclase in leukocytes. The order of potency reported by Bourne and Melmon is discrepant with not only the data in the present study but with the vast majority of data in the literature on P-adrenergic mediated processes in which isoproterenol is significantly more potent than epinephrine. The explanation for this discrepancy is not understood at this time. (Table II) . The small number of polymorphonuclear leukocytes contaminating the mononuclear cell preparations (2%) contributes negligibly to the total binding. Specific binding to the mononuclear cell preparations is not significantly altered by depletion of the monocyte population (Table II) . Thus the amount of (-) [5H]alprenololboundpermilligrammonocyteprotein is less than or equal to that bound per milligram lymphocyte protein. Since the number of monocytes (12%) in a mononuclear cell preparation is small relative to the number of lymphocytes present (86%), most of the total binding is accounted for by binding to the lymphocytes. This is in marked contrast with the binding of 'I-insulin to mononuclear leukocyte preparations which has been demonstrated to be mostly due to the monocytes present.
The existence of (3-adrenergic receptors in human leukocytes has been indirectly demonstrated previously by adenylate cyclase activation studies (5) and by blast transformation studies (20) (21) (22) (23) . Although the physiological functions of the ft-adrenergic receptors in lymphocytes have not been fully elucidated, 8-adrenergic receptor-mediated changes in cyclic adenosine 3',5'-monophosphate levels are thought to play a role in modulating cytolytic activity of lymphocytes (22) , antibody production by lymphocytes (24) , and lymphocyte maturation (25) .
The direct identification of P-adrenergic receptors in these preparations from human circulating cells is significant in several respects. First, it demonstrates the feasibility of extending to human tissues binding methods originally developed in amphibian (8, 9) and avian (26, 27) erythrocytes. Second, the ability to characterize and quantitate P-adrenergic receptors in these preparations provides a method for the study of possible P-adrenergic receptor defects in human disease. ACKNOWLEDGMENTS
